The Indian diabetes battleground is experiencing a fresh wave of firepower, with both domestic and multinational pharma giants unleashing a barrage of new anti-diabetic drugs.
From cutting-edge DPP-4 inhibitors to extended-release GLP-1 agonists, these new chips on the block have struck a chord and resonate well, some being priced at a 70% reduction compared to patented drugs, reports The Pharma Letter’s India correspondent.
With an economical alternative to an injectable drug for diabetes and obesity, Glenmark Pharmaceuticals (BOM: 532296) introduced a version of the diabetes medication liraglutide in India, part of the glucagon-like peptide-1 receptor agonists (GLP-1R) class.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze